JAK2V617F allele burden is associated with transformation to myelofibrosis

Maya Koren-Michowitz, Joseph Landman, Yoram Cohen, Naomi Rahimi-Levene, Ophira Salomon, Maria Michael, Ninette Amariglio, Arnon Nagler

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

The JAK2V617F mutation has emerged in recent years as a diagnostic as well as treatment target in patients with polycythemia vera (PV). We analyzed JAK2V617F allele burden (JAK2V617F) in a Jewish population with PV. Results were correlated with disease symptoms and complications. Median JAK2V617F was 48% and 54% in patients of Ashkenazi and non-Ashkenazi origin, respectively (p = 0.75). Higher JAK2V617F was seen in patients with imaging-proven splenomegaly (p = 0.01). A correlation between JAK2V617F and the weekly hydoxyurea dose needed for disease control was found (p = 0.043). In addition, a trend for higher allele burden in patients with longer disease duration (p = 0.064) and those treated with cytoreductive drugs other than hydroxyurea (p = 0.056) was noted. Higher JAK2V617F was seen in patients with transformation to myelofibosis (p = 0.0001), but not in patients with vascular complications. JAK2V617F may assist in prognostic stratification of patients with PV.

Original languageEnglish
Pages (from-to)2210-2213
Number of pages4
JournalLeukemia and Lymphoma
Volume53
Issue number11
DOIs
StatePublished - Nov 2012
Externally publishedYes

Keywords

  • Ashkenazi
  • JAK2V617F
  • PPVMF
  • neoplasm
  • polycythemia vera

Fingerprint

Dive into the research topics of 'JAK2V617F allele burden is associated with transformation to myelofibrosis'. Together they form a unique fingerprint.

Cite this